Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome

Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S23-34. Epub 2011 May 11.

Abstract

Objectives: Churg-Strauss syndrome (CSS) is a rare systemic vasculitis associated with eosinophilia and granuloma formation. The contribution of individual T-helper cell lineages in pathogenesis of CSS is unknown. We hypothesised that in CSS an imbalance of major effector T-cell subpopulations takes place, and is further influenced by the mode of treatment.

Methods: We investigated the immunophenotype, cytokine production and transcriptome profile in peripheral blood lymphocytes (PBL) from 19 patients with stable CSS (10 were treated with glucocorticoids alone (CSS/GC), 9 with steroids and other immunosuppressive drugs (CSS/IS)), and 13 healthy controls. Furthermore, serum IL-5 and CCR4-active chemokines (CCL17, CCL22) were measured in six patients with active disease and upon remission.

Results: All CSS patients had decreased percentage of FoxP3+ regulatory T cells. In the CSS/GC group we found an increase in the Th17/Treg ratio and up-regulation of both Th2 and Th17 markers as evidenced by (1) over expression of Th2-related genes (GATA3, STAT6) in PBL, (2) elevated concentrations of serum IL-5 and CCL17, and (3) a concomitant increase in the number of Th17 cells, and secretion of IL-17A by stimulated PBL. The level of CCR4-active chemokines was increased in active-CSS, and correlated with blood eosinophilia. The combined treatment with steroids and other immunosuppressive drugs was associated with a significant decrease in both Th2-related chemokines and the number of Th17 cells.

Conclusions: Our results indicate that both Th2 and Th17 lineages are involved in the pathogenesis of CSS, while CCR4-active chemokines contribute to eosinophilia in the active disease. These phenomena are down regulated by immunosuppressive therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analysis of Variance
  • Case-Control Studies
  • Cells, Cultured
  • Chemokine CCL17 / blood
  • Churg-Strauss Syndrome / blood
  • Churg-Strauss Syndrome / drug therapy
  • Churg-Strauss Syndrome / genetics
  • Churg-Strauss Syndrome / immunology*
  • Cytokines / blood*
  • Drug Therapy, Combination
  • Female
  • Forkhead Transcription Factors / blood
  • GATA3 Transcription Factor / blood
  • GATA3 Transcription Factor / genetics
  • Gene Expression Profiling
  • Gene Expression Regulation
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunophenotyping
  • Immunosuppressive Agents / therapeutic use
  • Inflammation Mediators / blood*
  • Interleukin-17 / blood
  • Interleukin-5 / blood
  • Male
  • Middle Aged
  • Phenotype
  • Poland
  • Receptors, CCR4 / blood
  • STAT6 Transcription Factor / blood
  • STAT6 Transcription Factor / genetics
  • T-Lymphocytes, Regulatory / immunology
  • Th1 Cells / drug effects
  • Th1 Cells / immunology*
  • Th17 Cells / drug effects
  • Th17 Cells / immunology*
  • Treatment Outcome

Substances

  • CCL17 protein, human
  • CCR4 protein, human
  • Chemokine CCL17
  • Cytokines
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • GATA3 Transcription Factor
  • GATA3 protein, human
  • Glucocorticoids
  • IL17A protein, human
  • IL5 protein, human
  • Immunosuppressive Agents
  • Inflammation Mediators
  • Interleukin-17
  • Interleukin-5
  • Receptors, CCR4
  • STAT6 Transcription Factor
  • STAT6 protein, human